Second-Line Docetaxel + ASA404 for Advanced Urothelial Carcinoma

This is an interventional treatment trial for Urothelial Carcinoma focused on measuring Advanced Urothelial Carcinoma Read More

Inclusion Criteria:

• Histological or cytological proof of transitional cell carcinoma (TCC) of the bladder, urethra, ureter, or renal pelvis (urothelial carcinoma). Histology may be mixed, but still requires a component of TCC.
• Measurable disease according to RECIST (version 1.1) and obtained by imaging within 30 days prior to registration for protocol therapy. Note: Sites of measurable disease can not be within a previously irradiated site.
• Written informed consent and HIPAA authorization for release of personal health information.
• Age > 18 years at the time of consent.
• Must have received only one prior chemotherapy regimen, which must have included one of the following chemotherapeutic agents: cisplatin, carboplatin, or gemcitabine. Note: Prior chemotherapy may have been administered in the perioperative (neoadjuvant/adjuvant) or advanced/metastatic setting. Patients may have received prior treatment with paclitaxel.
• Females of childbearing potential and males must be willing to use an effective method of contraception (hormonal or barrier method of birth control; abstinence) from the time consent is signed until 12 weeks after treatment discontinuation.
• Females of childbearing potential must have a negative pregnancy test within 7 days prior to registration for protocol therapy.
• Females must not be breastfeeding.

Exclusion Criteria:

• No prior treatment with docetaxel.
• No symptomatic brain metastases. Patients with neurological symptoms must undergo a head CT scan or brain MRI to exclude brain metastasis. NOTE: Patients with treated brain metastasis must be off steroids and have completed radiation at least 14 days prior to registration for protocol therapy.
• No prior malignancy is allowed except for adequately treated basal cell or squamous cell skin cancer, in situ cervical cancer, Gleason < grade 7 prostate cancers, or other cancers for which the patient has been disease-free for at least 5 years
• No treatment with any investigational agent or chemotherapeutic agent within 30 days prior to registration for protocol therapy.
• No radiotherapy within 14 days prior to registration for protocol therapy. Patients must have recovered from all radiotherapy-related toxicities.
• No major surgery within 30 days prior to registration for protocol therapy (major surgery is defined by the use of general anesthesia).
• No minor surgery 14 days prior to registration for protocol therapy. NOTE: Insertion of a vascular access device is allowed.
• No history of any medical condition resulting in ≥ CTC grade 2 dyspnea.
• Patients without long QT syndrome
• No history of labile hypertension or poor compliance with anti-hypertensive regimen NOTE: No patients with systolic BP >140 mm Hg and/or diastolic BP > 90 mm Hg while on medication for hypertension.
• No presence of atrial tachyarrhythmia (e.g., atrial fibrillation, atrial flutter, multifocal atrial tachycardia, supraventricular tachycardia) if not effectively rate-controlled.
• No history of a sustained ventricular tachycardia
• No history of ventricular fibrillation or Torsades de Pointes
• No right bundle branch block and left anterior or posterior hemiblock (bifascicular block)
• No bradycardia defined as heart rate <50 beats per minute
• No concomitant use of drugs with risk of causing Torsades de Pointes.
• No concomitant use of drugs that are inducers and inhibitors of UGT1A9 and UGT2B7.